ITCI
Intra-Cellular Therapies Inc

5,903
Loading...
Loading...
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
860

Frequently Asked Questions

What is Market Cap of Intra-Cellular Therapies Inc?
What is the 52-week high for Intra-Cellular Therapies Inc?
What is the 52-week low for Intra-Cellular Therapies Inc?
What is Intra-Cellular Therapies Inc stock price today?
What was Intra-Cellular Therapies Inc stock price yesterday?
What is the PE ratio of Intra-Cellular Therapies Inc?
What is the Price-to-Book ratio of Intra-Cellular Therapies Inc?
What is the 50-day moving average of Intra-Cellular Therapies Inc?
How many employess does Intra-Cellular Therapies Inc has?

Latest ITCI News

View

Advertisement. Remove ads.

Advertisement. Remove ads.